APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood, former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors. “Jim is known in the industry for his long tenure as president and CEO […]
IPF Summit 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist (APT101) and its effects in models of acute and chronic lung injury
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
APIE Therapeutics appoints Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief business officer and chief medical officer, respectively.
RESI JPM 2022
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors with strategic channel partners.
In 2022, RESI returns to JP Morgan in its successful virtual format, being held January 11-13, 2022. The week of JPM has been described as the World Series of early-stage life science and healthcare, bringing innovators, investors, and industry experts together to build relationships and make deals, which makes it a highly competitive event.
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
RESI Conference 2021
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors with strategic channel partners.
RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health.
RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.
APIE Therapeutics will participate in the Innovator’s Pitch Challenge Session. The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session.
Longevity Health & Innovation Conference
Longevity, Health & Innovation (LHI) is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. LHI brings fundraising startups together with investors in longevity innovation to make deals in order that today’s seniors live longer, healthier lives.
APIE Therapeutics will participate in the Innovator’s Pitch Challenge Session. The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session.
